65,437 trials
Dupuytren's Disease
Primary: Percent Change From Baseline in Surface Area and Volume of the Treated Nodule at Day 57 Using Caliper Measurements — -81.61; -80.11; -58.30; -41.76 percentage of change…
Febrile Neutropenia · Cancer · Breast Cancer
Primary: Chemotherapy Toxicity (%FN Risk) — 154; 650; 640; 3 participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: The Rate of Complete Remission (CR+CRi) — 0.143; 0.278; 0.15 proportion of participants
Substance Abuse
Primary: Main Study, Adolescent Drug Use — 3; 3 days of drug use 28 days prior baseline — p=.27
Renal Failure
Primary: Pharmacokinetics (AUC) of LCP-Tacro Compared to Prograf After Kidney Transplantation — 382.72; 147.82 ng*hr/mL
Atopic Dermatitis
Primary: Change From Baseline to Day 15 in Modified Local SCORing Atopic Dermatitis (SCORAD) — -2.30; -1.75 Scores on a scale — p=0.276
Depression · Depressive Disorder, Major
Primary: Change in Depression Severity — -5.4; -3.7 units on a scale — p=.003
Breast Cancer
Primary: Patholocial Response to Chemotherapy — 6; 42 participants
Hepatitis C · Pharmacokinetics
Primary: Number of Participants With Investigator Defined Drug-related Adverse Events in Triple Combination Therapy — 3; 6; 6; 5 participants
Labor Pain
Primary: Early Profound Fetal Bradycardia — 8; 14 participants — p=0.18
Non-small Cell Lung Cancer
Primary: Response Rate — 32 Percentage of Participants
Atrial Fibrillation
Primary: Stroke (Hemorrhagic, Ischemic) — 9.15; 13.19 Events per 1000 person-years
Acute Myelogenous Leukemia
Primary: Disease-free Survival at 6 Months — 0; 4 participants
Moderate or Severe Submental Fullness
Primary: Change From Baseline in Pain Visual Analog Scale Scores — 0.0; 0.0; 0.0; 0.0 units on a scale — p=0.6803
Spinal Muscular Atrophy
Primary: Safety and Tolerability of Sodium Phenylbutyrate in Neonates and Infants With SMA — 1; 8; 0; 1 Participants